| Attribute |
Value |
| 52 Week Change |
-0.5339366 |
| Address1 |
1 Commonwealth Lane |
| Address2 |
No. 08-22 |
| All Time High |
9.25 |
| All Time Low |
0.68 |
| Ask |
1.35 |
| Ask Size |
1 |
| Average Daily Volume10 Day |
14,830 |
| Average Daily Volume3 Month |
18,952 |
| Average Volume |
18,952 |
| Average Volume10Days |
14,830 |
| Beta |
0.021 |
| Bid |
1.07 |
| Bid Size |
3 |
| Book Value |
0.4272251 |
| City |
Singapore |
| Compensation As Of Epoch Date |
1,735,603,200 |
| Country |
Singapore |
| Crypto Tradeable |
0 |
| Currency |
USD |
| Current Price |
0.9604 |
| Current Ratio |
5.165 |
| Custom Price Alert Confidence |
HIGH |
| Date Short Interest |
1,782,777,600 |
| Day High |
1.0299 |
| Day Low |
0.9604 |
| Debt To Equity |
7.041 |
| Display Name |
CytoMed Therapeutics |
| Earnings Timestamp End |
1,745,870,400 |
| Earnings Timestamp Start |
1,745,870,400 |
| Ebitda |
-3,849,627 |
| Ebitda Margins |
0.0 |
| Enterprise To Ebitda |
-2.612 |
| Enterprise To Revenue |
11.682 |
| Enterprise Value |
10,056,323 |
| Eps Forward |
-0.15 |
| Eps Trailing Twelve Months |
-0.26 |
| Esg Populated |
0 |
| Exchange |
NCM |
| Exchange Data Delayed By |
0 |
| Exchange Timezone Name |
America/New_York |
| Exchange Timezone Short Name |
EDT |
| Fifty Day Average |
1.04682 |
| Fifty Day Average Change |
-0.08642006 |
| Fifty Day Average Change Percent |
-0.08255484 |
| Fifty Two Week Change Percent |
-53.39366 |
| Fifty Two Week High |
3.68 |
| Fifty Two Week High Change |
-2.7196002 |
| Fifty Two Week High Change Percent |
-0.7390218 |
| Fifty Two Week Low |
0.68 |
| Fifty Two Week Low Change |
0.28039998 |
| Fifty Two Week Low Change Percent |
0.41235292 |
| Fifty Two Week Range |
0.68 - 3.68 |
| Financial Currency |
SGD |
| First Trade Date Milliseconds |
1,681,479,000,000 |
| Float Shares |
3,692,956 |
| Forward Eps |
-0.15 |
| Forward P E |
-6.402666 |
| Free Cashflow |
-2,715,337 |
| Full Exchange Name |
NasdaqCM |
| Full Time Employees |
42 |
| Gmt Off Set Milliseconds |
-14,400,000 |
| Gross Margins |
0.89572996 |
| Gross Profits |
771,088 |
| Has Pre Post Market Data |
1 |
| Held Percent Insiders |
0.68779 |
| Held Percent Institutions |
0.00179 |
| Implied Shares Outstanding |
11,832,835 |
| Industry |
Biotechnology |
| Industry Disp |
Biotechnology |
| Industry Key |
biotechnology |
| Ipo Expected Date |
2,023-04-14 |
| Is Earnings Date Estimate |
0 |
| Language |
en-US |
| Last Fiscal Year End |
1,767,139,200 |
| Long Business Summary |
CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord-derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore; and Business and Research Collaboration Agreement with SunAct Cancer Institute Private Limited to conduct clinical trials for the GMP grade CTM-GDT. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore. |
| Long Name |
CytoMed Therapeutics Limited |
| Market |
us_market |
| Market Cap |
11,364,255 |
| Market State |
POSTPOST |
| Max Age |
86,400 |
| Message Board Id |
finmb_647650276 |
| Most Recent Quarter |
1,767,139,200 |
| Net Income To Common |
-3,980,457 |
| Next Fiscal Year End |
1,798,675,200 |
| Non Diluted Market Cap |
12,187,820 |
| Open |
1.0298 |
| Operating Cashflow |
-3,697,463 |
| Operating Margins |
-5.3525 |
| Payout Ratio |
0.0 |
| Phone |
65 6250 7738 |
| Previous Close |
1.0 |
| Price Hint |
4 |
| Price To Book |
2.2479951 |
| Price To Sales Trailing12 Months |
13.201233 |
| Profit Margins |
0.0 |
| Quick Ratio |
3.141 |
| Quote Source Name |
Delayed Quote |
| Quote Type |
EQUITY |
| Recommendation Key |
none |
| Region |
US |
| Regular Market Change |
-0.039600015 |
| Regular Market Change Percent |
-3.9600015 |
| Regular Market Day High |
1.0299 |
| Regular Market Day Low |
0.9604 |
| Regular Market Day Range |
0.9604 - 1.0299 |
| Regular Market Open |
1.0298 |
| Regular Market Previous Close |
1.0 |
| Regular Market Price |
0.9604 |
| Regular Market Time |
1,783,972,800 |
| Regular Market Volume |
23,792 |
| Return On Assets |
-0.29312 |
| Return On Equity |
-0.50276 |
| Revenue Growth |
0.469 |
| Revenue Per Share |
0.074 |
| Sand P52 Week Change |
0.20847368 |
| Sector |
Healthcare |
| Sector Disp |
Healthcare |
| Sector Key |
healthcare |
| Shares Outstanding |
11,832,835 |
| Shares Percent Shares Out |
0.0032 |
| Shares Short |
37,906 |
| Shares Short Previous Month Date |
1,780,012,800 |
| Shares Short Prior Month |
67,963 |
| Short Name |
CytoMed Therapeutics Limited |
| Short Percent Of Float |
0.0108 |
| Short Ratio |
1.93 |
| Source Interval |
15 |
| Symbol |
GDTC |
| Total Cash |
2,095,489 |
| Total Cash Per Share |
0.177 |
| Total Debt |
482,562 |
| Total Revenue |
860,848 |
| Tradeable |
0 |
| Trailing Annual Dividend Rate |
0.0 |
| Trailing Annual Dividend Yield |
0.0 |
| Trailing Eps |
-0.26 |
| Trailing Peg Ratio |
None |
| Triggerable |
1 |
| Two Hundred Day Average |
1.357575 |
| Two Hundred Day Average Change |
-0.39717507 |
| Two Hundred Day Average Change Percent |
-0.29256216 |
| Type Disp |
Equity |
| Volume |
23,792 |
| Website |
https://w2.cytomed.sg |
| Zip |
149,544 |